The focal adhesion gene list had an enrichment score of 2, and as FAK has previously been identified as a potential therapeutic target in several cancers [37], the focal adhesion kinase (FAK) signaling pathway was selected as a possible target to inhibit CLL migration. The gene discussed is PTK2; the disease is B-cell chronic lymphocytic leukemia.